ATHE
Price
$2.90
Change
-$0.03 (-1.02%)
Updated
Apr 4 closing price
Capitalization
32.13M
RXRX
Price
$4.24
Change
-$0.57 (-11.85%)
Updated
Apr 4 closing price
Capitalization
1.7B
31 days until earnings call
Ad is loading...

ATHE vs RXRX

Header iconATHE vs RXRX Comparison
Open Charts ATHE vs RXRXBanner chart's image
Alterity Therapeutics
Price$2.90
Change-$0.03 (-1.02%)
Volume$53.36K
Capitalization32.13M
Recursion Pharmaceuticals
Price$4.24
Change-$0.57 (-11.85%)
Volume$28.15M
Capitalization1.7B
ATHE vs RXRX Comparison Chart
Loading...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHE vs. RXRX commentary
Apr 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHE is a Buy and RXRX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 07, 2025
Stock price -- (ATHE: $2.90 vs. RXRX: $4.24)
Brand notoriety: ATHE and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHE: 10% vs. RXRX: 112%
Market capitalization -- ATHE: $32.13M vs. RXRX: $1.7B
ATHE [@Biotechnology] is valued at $32.13M. RXRX’s [@Biotechnology] market capitalization is $1.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHE’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • ATHE’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATHE and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RXRX’s TA Score shows that 4 TA indicator(s) are bullish.

  • RXRX’s TA Score: 4 bullish, 6 bearish.

Price Growth

ATHE (@Biotechnology) experienced а -15.70% price change this week, while RXRX (@Biotechnology) price change was -27.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.00%. For the same industry, the average monthly price growth was -16.69%, and the average quarterly price growth was -18.23%.

Reported Earning Dates

ATHE is expected to report earnings on May 31, 2023.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-11.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.7B) has a higher market cap than ATHE($32.1M). ATHE YTD gains are higher at: -12.387 vs. RXRX (-37.278). ATHE has higher annual earnings (EBITDA): -19.88M vs. RXRX (-426.72M). RXRX has more cash in the bank: 594M vs. ATHE (4.54M). ATHE has less debt than RXRX: ATHE (106K) vs RXRX (108M). RXRX has higher revenues than ATHE: RXRX (58.5M) vs ATHE (0).
ATHERXRXATHE / RXRX
Capitalization32.1M1.7B2%
EBITDA-19.88M-426.72M5%
Gain YTD-12.387-37.27833%
P/E RatioN/AN/A-
Revenue058.5M-
Total Cash4.54M594M1%
Total Debt106K108M0%
FUNDAMENTALS RATINGS
ATHE: Fundamental Ratings
ATHE
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
42
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RXRX
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 14 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
87%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NEQIX10.81-0.64
-5.59%
Neuberger Berman U.S. Equity Impact I
MRERX42.23-2.55
-5.69%
MFS Core Equity R2
WMLIX27.40-1.73
-5.94%
Wilmington Large-Cap Strategy Instl
NWAUX13.89-0.88
-5.96%
Nationwide GQG US Quality Eq A
MYSPX54.00-3.43
-5.97%
NYLI S&P 500 Index Investor Class

ATHE and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHE has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHE
1D Price
Change %
ATHE100%
-1.12%
EYPT - ATHE
54%
Loosely correlated
-7.62%
SLDB - ATHE
38%
Loosely correlated
-8.52%
BCLI - ATHE
33%
Loosely correlated
-6.50%
RXRX - ATHE
29%
Poorly correlated
-11.85%
CVM - ATHE
29%
Poorly correlated
+8.65%
More